"It doesn't cure the disease, but it [neuroAD] does make the brain circuits work better, and this leads to a striking improvement in cognitive abilities for day-to-day tasks…"
Alvaro Pascual-Leone, MD, PhD, Beth Israel Deaconess Medical Center, Harvard Medical School
Modify the course of disease progression
The potential to modify the course of disease progression in patients with mild to moderate Alzheimer’s Disease symptoms represents a breakthrough for your patients. With evidence indicating that neuroAD potentially not only brings short term benefit, but also prevent further deterioration of the patients for up to 1-year; thus, you can potentially prolong your patients’ independence and improve their quality of life.
The neuroAD system is based on Neuronix’s technology, combining two modalities concurrently:
Focused Transcranial Magnetic Stimulation (TMS) is used to stimulate targeted regions of the brain responsible for various cognitive functions that have been impaired by Alzheimer’s Disease. This stimulation induces LTP (Long-Term Potentiation), which is associated with learning and memory processes, and makes these areas of the brain more receptive to Cognitive Training. Tailored Cognitive Training targets those same brain regions while they are being magnetically stimulated.
The concurrent use of these two modalities has been shown to have a synergistic effect. Not only do patients experience improvement in cognitive capabilities, daily functions and decision-making; neuroAD Therapy System potentially modifies the actual course of disease progression.
Safe and effective
neuroAD treatments can be administered safely in conjunction with current pharmacological therapies for Alzheimer’s Disease, so that patient can enjoy the benefits of both. And, unlike medications, no serious adverse events have been reported with the neuroAD system.
neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.